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Early Recurrent Ischemic Stroke Complicating Intravenous
Thrombolysis for Stroke
Incidence and Association With Atrial Fibrillation
Mostafa Awadh, MB BCh; Niall MacDougall, MRCP; Celestine Santosh, FRCR;
Evelyn Teasdale, FRCR; Tracey Baird, MRCP; Keith W. Muir, MD, FRCP
Background and Purpose—Mechanisms of early neurologic deterioration after treatment with intravenous, recombinant,
tissue-type plasminogen activator (IV rt-PA) include symptomatic intracerebral hemorrhage (SICH) and early recurrent
ischemic stroke. We observed a number of cases of acute deterioration due to recurrent ischemic events.
Methods—We undertook a single-center, retrospective analysis of consecutive acute stroke patients treated with IV rt-PA
between January 2006 and December 2008 to define the incidence of early neurologic deterioration (4-point drop on
the National Institutes of Health Stroke Scale within 72 hours) and its mechanism. Deterioration was attributed to SICH
when associated with a PH1 or PH2 hemorrhage on postdeterioration computed tomography scans, to recurrent ischemic
stroke when there was clinical and radiologic evidence of a new territorial infarction or new vessel occlusion, and
otherwise to evolution of the incident stroke.
Results—Of 228 consecutive IV rt-PA–treated patients, 34 (15%) developed early neurologic deterioration, 18 (8%)
secondary to incident strokes 10 (4.4%) due to SICH, and 6 (2.6%) due to early recurrent ischemic events, which were
significantly associated with atrial fibrillation (present in 5 of 6 patients; 4 paroxysmal, 1 permanent). In 4 patients,
sudden clinical deterioration developed during or shortly after IV rt-PA infusion, and in 2, deterioration developed 3
days later. All died 2 days to 2 weeks later. The single case without atrial fibrillation had a recurrent, contralateral,
middle cerebral artery stroke during IV rt-PA infusion and multiple high-signal emboli detected by transcranial Doppler.
Early recurrent ischemic stroke accounted for 5 of 12 (42%) cases of early neurologic deterioration in patients with atrial
fibrillation.
Conclusion—In this single-center series, the incidence of early recurrent ischemic stroke after IV rt-PA was 2.6% and was
associated with previous atrial fibrillation. (Stroke. 2010;41:1990-1995.)
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Early neurologic deterioration (END) after acute ischemicstroke is common and is associated with a poor out-
come.1 Whereas END has no standardized definition, a drop
of 4 points or more on the National Institutes of Health Stroke
Scale (NIHSS) within the first 48 to 72 hours after acute
stroke1,2 has been commonly used. Mechanisms of deteriora-
tion include brain swelling after large infarction, and hemor-
rhagic transformation. Late deterioration has predominantly
systemic causes.3 When END occurs after intravenous (IV)
thrombolysis with recombinant tissue-type plasminogen acti-
vator (rt-PA), this usually raises the possibility of symptom-
atic intracranial hemorrhage (SICH), the most common safety
concern of treatment. Randomized, controlled trials and
registries have accordingly concentrated on the risk of SICH
but offer only a limited description of alternative mechanisms
of END. Arterial reocclusion accounts for some cases of END
after thrombolysis, but the clinical scenario is more often
deterioration after initial improvement rather than END
alone.4,5
Embolic stroke shortly after systemic thrombolysis has
been described in acute myocardial ischemia and prosthetic
valve thrombosis and more recently in a few cases of acute
ischemic stroke. We describe a series of cases wherein early
recurrent ischemic stroke (ERIS), confirmed clinically and
radiologically, occurred shortly after IV rt-PA, and compare
the incidence and clinical associations with other causes of
END.
Subjects and Methods
We reviewed the clinical and imaging data of all stroke patients
treated with IV rt-PA for 3 years (January 2006 to December 2008)
at a single center. All cases were registered with the Safe Implemen-
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tation of Thrombolysis register. Demographic and clinical data were
extracted from the local Safe Implementation of Thrombolysis
registry and hospital records.
Patients with ischemic stroke were treated with standard-dose IV
alteplase according to the National Institute of Neurological Disor-
ders and Stroke schedule and criteria,6 with the exception that no age
restriction was applied and that treatment was allowed up to 4.5
hours after onset, provided that there were no other contraindications
in either situation. Routine pretreatment imaging was performed by
noncontrast computed tomography (CT), with follow-up brain im-
aging 24 hours after treatment and additional imaging when
clinically indicated. Transcranial Doppler ultrasound was used to
monitor middle cerebral artery (MCA) flow in some cases during
alteplase infusion.
We defined significant END as a drop in NIHSS score of 4 points
or more within 72 hours after presenting stroke. SICH was consid-
ered to be the cause when a parenchymal hematoma (PH1 or PH2)7
was present on posttreatment CT. ERIS was diagnosed when there
was both clinical and imaging evidence of ischemic stroke in an
independent arterial territory, so as to exclude deficits explainable by
arterial reocclusion, proximal extension, or distal embolism of the
original thrombus. Cases of deterioration without either SICH or
recurrent ischemic stroke were considered to be related to the
incident stroke.
Statistical Analysis
Descriptive statistics present normally distributed variables as
meanSD and nonnormally distributed variables as median and
interquartile range. Proportions are given with 95% CIs. Binary
logistic regression was undertaken with the dependent variables of
ERIS or SICH and independent variables that included atrial fibril-
lation (AF), hypertension, age, smoking, NIHSS score, prior antico-
agulant/antiplatelet use, diabetes, and previous history of transient
ischemic attack or stroke. Variables were entered into a forward
stepwise conditional model.
Results
Data from 228 consecutive patients were reviewed. Clinical
characteristics are summarized in Table 1. AF (persistent,
paroxysmal, or transient) was documented in nearly one third
of all patients (32.4%). Thirty-four patients (15%; 95% CI,
10% to 19.5%) developed neurologic deterioration within 72
hours of treatment, 10 (4.4%) due to SICH, 6 (2.6%) with
evidence of ERIS, and 18 patients (8%) with neither cause,
therefore attributed to evolution of their incident stroke.
Table 2 compares the demographic and premorbid clinical
data among the 3 groups of END patients. Premorbid AF was
notably common (83.3%) in those with ERIS, and conversely,
the incidence of ERIS was significantly higher (Table 1) in
those with documented AF (6.8%; 95% CI, 2.6% to 15.2%)
compared with those without a history of AF (0.6%; 95% CI,
0% to 3.9%; odds ratio11.1; 95% CI, 1.27 to 96.7,
P0.0146) and also accounted for 5 of 12 cases of END in
patients with AF (42%), compared with only 1 of 22 cases of
END in those without AF (odds ratio15.0; 95% CI, 1.49 to
151.3; P0.0136). In logistic regression, only a history of AF
was associated with ERIS (odds ratio11.1; 95% CI, 1.27 to
96.7; P0.029). END due to SICH was associated with prior
anticoagulant use and a history of diabetes.
Table 1. Basic Clinical Data for All Ischemic Stroke Patients
Treated With IV rt-PA
All
Patients
Patients
With AF
Patients
Without AF
N/n (%) 228 (100%) 74 (32.4%) 154 (67.6%)
Age, meanSD, y 69.513 7610 66.413.4
Male, no. (%) 121 (53%) 30 (40%) 91 (59%)
Medical history, no. (%)
Hypertension 151 (66%) 52 (70%) 99 (64%)
Diabetes mellitus 24 (10%) 12 (16.2%) 12 (7.8%)
Hyperlipidemia 48 (21%) 14 (19%) 34 (22%)
Cigarette smoking 56 (24.5%) 11 (15%) 45 (29%)
Previous TIA or stroke 45 (19.7%) 13 (17.5%) 32 (20.8%)
Aspirin use 105 (46%) 44 (59.5%) 61 (39.6%)
Other antiplatelet agent 22 (9.5%) 6 (8%) 16 (10%)
Anticoagulants 7 (3%) 5 (6.7%) 2 (1.3%)
Stroke characteristics
NIHSS, median (IQR) 14 (8–20) 14 (8–19) 14.5 (7–20)
Time to treatment,
meanSD min
17038 162.732 173.340
END due to 34 (15%) 12 (16.2%) 22 (14.3%)
Incident stroke 18 (8%) 4 (5.4%) 14 (9%)
SICH 10 (4.4%) 3 (4%) 7 (4.5%)
ERIS 6 (2.6%) 5 (6.8%) 1 (0.6%)
Data include those for patients with a history of AF, including paroxysmal AF,
and those with no evidence of AF. TIA indicates transient ischemic attack; IQR,
interquartile range. Other abbreviations are as defined in text.
Table 2. Basic Clinical Data for Acute Stroke Patients Who
Developed END After Treatment With IV rt-PA
Mode of END
Incident Stroke SICH ERIS
n (%) 18 (8%) 10 (4.4%) 6 (2.6%)
Age, meanSD, y 69.513 70.77 727.5
Male, no. (%) 9 (50%) 5 (50%) 3 (50%)
Medical history
Hypertension 11 (61%) 9 (90%) 3 (50%)
Diabetes mellitus 1 (5.5%) 3 (30%) 1 (16.6%)
Hyperlipidemia 3 (16.6%) 1 (10%) 1 (16.6%)
Cigarette smoking 5 (27.7%) 2 (20%) 3 (50%)
Previous TIA or
stroke
5 (33.3%) 4 (40%) 3 (50%)
Premorbid AF 4 (22%) 3 (30%) 5 (83.3%)
Aspirin use 7 (39%) 6 (60%) 2 (33.3%)
Other antiplatelet
agent
3 (16.6%) 2 (20%) 2 (33%)
Anticoagulants
before stroke
0 (0%) 2 (20%) 0 (0%)
Stroke characteristics
and outcome
NIHSS, median (IQR) 15 (7, 21.25) 18 (10.25, 25.5) 13 (9.25, 18.25)
Onset to treatment
time, meanSD, min
162.526 186.716 17625
3-month mortality,
no. (%)
9 (50%) 9 (90%) 6 (100%)
TIA indicates transient ischemic attack; IQR, interquartile range. Other
abbreviations are as defined in text.
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The clinical features of the 6 cases of ERIS are detailed in
Table 3. On admission, 5 of 6 had documented AF (4
paroxysmal and 1 permanent). The specific reasons for prior
pacemaker use in 2 cases were not documented. There was no
evidence of acute or recent myocardial ischemia on the
admission ECG. All patients died 2 days to 2 weeks after first
stroke (mean, 8 days). In 4 cases, deterioration occurred
suddenly during or immediately after IV alteplase infusion,
and 2 cases occurred 3 days later. In 5 cases, there was a
reduced level of consciousness. Examples of supporting
imaging studies are shown in the Figure.
Discussion
The incidence of END after IV rt-PA treatment in our series
(15%) is consistent with that reported by others, but we found
a higher incidence of ERIS than has been reported previously.
Although the incidence of ERIS was low and certainly should
not delay thrombolysis in suitable patients, ERIS accounted
for a significant proportion of deterioration and was only
slightly less frequent than SICH. A strong association with
AF was also noted.
Secondary embolism after systemic thrombolysis, includ-
ing ischemic stroke, is recognized as an uncommon compli-
cation of thrombolysis for acute myocardial ischemia,8–14
prosthetic valvular thrombosis,15–18 or massive pulmonary
embolism19 and has been presumed to occur as a consequence
of the disintegration of preexisting intracardiac or valvular
thrombus. Preexisting left ventricular thrombus has been
documented by echocardiography before ischemic stroke
complicating thrombolysis for acute myocardial ische-
mia,10,13 with a disappearance or reduction in thrombus
volume after stroke. Possible embolization to other vascular
beds has also been reported after IV rt-PA for ischemic
stroke, including acute myocardial infarction,20,21 peripheral
arterial embolism,22 or embolism to the external carotid
artery.23 Embolic sources include intracardiac (intraventricu-
lar, intra-atrial, or valvular) or proximal aortic14 thrombus. In
most previously reported cases, the embolic event occurred
during or soon after rt-PA infusion, consistent with the
majority of our cases.
Although the presence of intracardiac thrombi has been
suggested as a relative contraindication for thrombolysis for
stroke, secondary embolic stroke after systemic thrombolysis
is rare, even in the presence of known intraventricular
thrombi24 (no strokes in 37 consecutive patients treated with
streptokinase for acute myocardial ischemia24 and 1 late
ischemic stroke among 5 consecutive cases after IV rt-PA for
acute stroke25).
Applying our definition of ERIS, which attempts to ex-
clude cases of proximal extension, reocclusion, or distal
embolization in the same vascular territory, we identified
only 5 cases in the literature.26–29 Mechanisms of stroke
Table 3. Demography, Clinical Features, and Outcomes of Patients Who Developed ERIS After IV rt-PA
Case
Sex/
Age, y
History of
AF
Other Vascular
Risk Factors
Antiplatelet
Use Before
Admission OCSP NIHSS
ECG on
Admission
Pretreatment
CT
Onset-to-
Treatment
Time, min
Symptoms of
Recurrent Stroke
Time From
Treatment Onset
to Recurrent
Stroke, min
Follow-Up
CT
Other
Investigation and
Management
Final
Outcome
(Days From
Onset)
1 F/80 PAF IHD, smoking Clopidogrel L PACS 13 NSR L MCA EIC 160 Coma, extension
of 4 limbs
80 L MCA
infarct,
hyperdense
BA
Angiography and
IA thrombolysis
of BA
Death (6)
2 M/64 No HTN, smoking No R TACS 18 NSR Recent L
occipital
infarct,
hyperdense
R MCA
210 Coma, extension
of 4 limbs
60 R MCA
infarct,
hyperdense
L MCA
TCD: Low R
MCA flow,
microemboli
Death (3)
3 M/62 Permanent
AF
HOCM No R TACS 19 AF Nil 165 New
contralateral
hemiparesis
45 Normal CTA: occluded L
MCA,
recanalized R
MCA
Death (2)
4 F/79 PAF with
pacemaker
IHD, migraine,
DVT
Aspirin L PACS 4 PAF Nil 205 Coma, extension
of 4 limbs
3 days L MCA
infarct,
hyperdense
BA
CTA: normal
(before
deterioration)
Death (10)
5 M/74 PAF with
pacemaker
IHD, HTN, DM,
CHF, smoking
Clopidogrel L PACS 13 AF Nil 150 Coma, new
contralateral
hemiparesis
40 L MCA and
PCA acute
infarcts
CTP: L MCA
ischemia, no
PCA ischemia,
CTA: L MCA
anterior branch
occlusion and
irregular calcific
atheroma
occluding L VA
Death (15)
6 F/73 PAF HTN,
hyperlipidemia
Aspirin R PACS 11 NSR Nil 165 Seizures, coma,
new
contralateral
hemiparesis
3 days R MCA
early
infarct
MRI (DWI): L
acute MCA and
R subacute MCA
infarctions
Death (11)
OCSP indicates Oxfordshire Community Stroke Project; PAF, paroxysmal AF; IHD, ischemic heart disease; HTN, hypertension; HOCM, hypertrophic obstructive
cardiomyopathy; DVT, deep venous thrombosis; DM, diabetes mellitus; CHF, congestive heart failure; L, left; PACS, partial anterior circulation stroke; R, right; TACS,
total anterior circulation stroke; NSR, normal sinus rhythm; EIC, early ischemic changes; BA, basilar artery; PCA, posterior cerebral artery; IA, intra-arterial; TCD,
transcranial Doppler; CTA, CT angiography; CTP, CT perfusion; VA, vertebral artery; MRI, magnetic resonance imaging; and DWI, diffusion-weighted imaging.
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recurrence included calcific embolism from an aortic valve.26
In only 2 cases was AF documented.27,29 However, a central
embolic source was inferred from multifocal thrombotic
vessel occlusions in 2 others.28 Alternative mechanisms such
as proximal arterial thrombi have been present in other cases
with a history of paroxysmal AF.30
Documented AF was unusually prevalent in our patients
and was associated with ERIS. This mechanism accounted for
42% of END cases after thrombolysis in AF patients. Most
events caused sudden neurologic deterioration with impaired
consciousness and occurred during or shortly after rt-PA
infusion. Without echocardiography, the source is specula-
Figure. A, Case 5, presented with symptoms of left MCA territory ischemia and CTP (a, b), confirming increased mean transit time in
the left frontal cortex with no other hypoperfusion. C, Noncontrast CT scan 24 hours after deterioration with ischemic changes in both
the left MCA and posterior cerebral artery territories. B, CT angiography in case 3 after clinical deterioration shows recanalization of the
right MCA (presenting symptomatic vessel) and a proximal left MCA filling defect, consistent with the development of a new contralat-
eral hemiparesis. C, Magnetic resonance imaging of case 6 performed after acute deterioration occurred with generalized seizures 3
days after treatment. T2 fluid-attenuated inversion recovery (a) and diffusion-weighted (b) imaging shows a subacute right MCA infarc-
tion (presenting stroke) and an acute left MCA infarct.
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tive, and although the time course and clinical associations
are consistent with fragmentation of preexisting intra-atrial
clot by rt-PA, we cannot exclude the possibility of embolism
from other sources known to be common in patients with AF,
such as aortic arch atheroma, or intraventricular thrombus
secondary to myocardial infarction, although we found no
ECG evidence of recent myocardial ischemia in any case.
The single case in our series without documented AF had
clinical and radiological evidence of preceding multiple-
territory ischemic events, including recent transient ischemic
attack, and had multiple, hyperintense, transient signals
consistent with emboli during transcranial Doppler monitor-
ing, implicating a central embolic source. In case 5, an
irregular, occlusive, calcific thrombus of the vertebral artery
was documented before recurrent ipsilateral posterior cere-
bral artery infarction, so artery-to-artery embolism is a
possible alternative mechanism.
Admission ECG did not show AF in all cases in our series,
and medical records provided evidence of prior diagnosis.
Previous reports of ERIS documented definite AF in only 2 of
5 cases, but this may only reflect limited availability of
previous medical history. The low sensitivity of single ECG
recordings for paroxysmal AF diagnosis is recognized.31
The uniformly poor outcome of ERIS almost certainly
reflects recognition bias in favor of severe events. Because
only a small proportion of new ischemic lesions detected on
diffusion-weighted magnetic resonance imaging are associ-
ated with clinical events,32 the true incidence of new events in
other arterial territories can be determined only by imaging
studies before and after thrombolysis. AF is recognized as a
poor prognostic factor for acute ischemic stroke, in the
severity of presentation and early mortality, either with33,34 or
without35–38 thrombolysis. Although other factors such as
hemodynamic instability and poorer cerebral perfusion may
be contributory,1,39 ERIS might also be a mechanism for this
poor prognosis among rt-PA–treated patients.
The implications for patient management are ambiguous in
the absence of a clear therapeutic intervention at present for
either prevention or rescue therapy. Echocardiographic
screening of patients would delay thrombolysis, and it as-
sumes a cardiac source for emboli that is unproven. Trans-
esophageal studies would be required to seek an atrial or atrial
appendage clot. The presence of AF on admission ECG alone
is insensitive, with low sensitivity and specificity. Both the
early timing of deterioration in several of our cases and the
increased risk of ICH as part of the natural history of
cardioembolic stroke suggest that early introduction of anti-
coagulants or antithrombotic therapy after IV rt-PA in pa-
tients with AF, even with documented intracardiac thrombus,
would unlikely be safe or effective. Awareness of second
embolic stroke may allow clinicians to consider interven-
tional treatment approaches in individual cases, which may be
justified in the light of a poor prognosis.
Disclosures
None.
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